Sea Pharmaceuticals
Sea Pharmaceuticals develops innovative oral treatments for neurological disorders like tinnitus and epilepsy.
Founded
2013Sea Pharmaceuticals develops innovative oral treatments for neurological disorders like tinnitus and epilepsy.
Founded with a mission to revolutionize neurotherapeutics, Sea Pharmaceuticals focuses on developing innovative oral treatments for neurological disorders such as tinnitus and epilepsy. The company is dedicated to inventing, discovering, and advancing research and development (R&D) to commercialize its proprietary synthetic small molecules. These novel treatments aim to address high medical need therapeutic neurology indications, including genetic disorders of the central nervous system (CNS).
Sea Pharmaceuticals has attracted notable experts in the field of neurology and pharmaceutical development, alongside significant investment from key stakeholders in the biotech industry. The company has achieved critical milestones in preclinical and clinical trials, demonstrating promising efficacy and safety profiles for its lead compounds. Through its pioneering work, Sea Pharmaceuticals is making a substantial impact on the treatment landscape for neurological disorders, offering hope to patients with limited therapeutic options.
Companies similar to Sea Pharmaceuticals include NeuroPro Therapeutics, Cerebral Therapeutics, Sound Pharmaceuticals and Prexa Pharmaceuticals.
Sea Pharmaceuticals was founded in 2013.
Sea Pharmaceuticals' headquarters is located in Cambridge, MA, US.
Sea Pharmaceuticals' most recent funding round was for $1.5M (USD) in January 2021.
As of Jan 29, 2021, Sea Pharmaceuticals has disclosed funding of $1.7M (USD). Undisclosed round amounts are excluded.
Sea Pharmaceuticals has 8 employees as of Feb 5, 2024.
